Literature DB >> 7625811

Concentration of pefloxacin in feces during infection prophylaxis in neutropenic patients.

J J van de Leur1, E J Vollaard, A J Janssen, A S Dofferhoff.   

Abstract

Pefloxacin (400 mg twice daily) was administered orally for infection prophylaxis in neutropenic patients. Diffusible fecal pefloxacin concentration was determined by bioassay during 24 neutropenic periods. The median diffusible fecal pefloxacin concentration was 187 micrograms/g. This concentration was comparable with those found in volunteers following oral and intravenous administration of pefloxacin (400 mg twice daily) (median of 171 and 155 micrograms/g, respectively). From this study, it is concluded that pefloxacin administered orally results in a predictable high diffusible fecal concentration which leads to effective elimination of susceptible aerobic gram-negative bacilli from the colonic flora.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625811      PMCID: PMC162706          DOI: 10.1128/AAC.39.5.1182

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Transintestinal elimination of ciprofloxacin.

Authors:  R Rohwedder; T Bergan; S B Thorsteinsson; H Scholl
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

Review 2.  Colonization resistance.

Authors:  E J Vollaard; H A Clasener
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 3.  Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens.

Authors:  J J Farmer; B R Davis; F W Hickman-Brenner; A McWhorter; G P Huntley-Carter; M A Asbury; C Riddle; H G Wathen-Grady; C Elias; G R Fanning
Journal:  J Clin Microbiol       Date:  1985-01       Impact factor: 5.948

Review 4.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 5.  Prevention of infection by ciprofloxacin in neutropenia.

Authors:  R E Warren; J Z Wimperis; T P Baglin; C E Constantine; R Marcus
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

6.  Infection prophylaxis in neutropenic patients with acute leukaemia--a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin.

Authors:  M Arning; H H Wolf; C Aul; A Heyll; R E Scharf; W Scheider
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

Review 7.  Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation.

Authors:  H A Clasener; E J Vollaard; H K van Saene
Journal:  Rev Infect Dis       Date:  1987 Mar-Apr

8.  Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy.

Authors:  R H Liang; R W Yung; T K Chan; P Y Chau; W K Lam; S Y So; D Todd
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 9.  Emerging role of quinolones in the prevention of gram-negative bacteremia in neutropenic cancer patients and in the treatment of enteric infections.

Authors:  E J Bow; T J Louie
Journal:  Clin Invest Med       Date:  1989-02       Impact factor: 0.825

10.  Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation.

Authors:  F Menichetti; R Felicini; G Bucaneve; F Aversa; M Greco; C Pasquarella; M V Moretti; A Del Favero; M F Martelli
Journal:  Bone Marrow Transplant       Date:  1989-09       Impact factor: 5.483

View more
  2 in total

Review 1.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

2.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

Authors:  J Carratala; A Fernandez-Sevilla; F Tubau; M A Dominguez; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.